X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ASTRAZENECA PHARMA ALEMBIC PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 29.5 105.2 28.1% View Chart
P/BV x 6.7 15.0 45.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
ALEMBIC PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs7921,285 61.6%   
Low Rs443634 69.9%   
Sales per share (Unadj.) Rs167.0189.6 88.1%  
Earnings per share (Unadj.) Rs38.2-0.2 -18,743.6%  
Cash flow per share (Unadj.) Rs42.03.8 1,092.3%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.968.6 123.7%  
Shares outstanding (eoy) m188.5225.00 754.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.75.1 73.0%   
Avg P/E ratio x16.2-4,712.7 -0.3%  
P/CF ratio (eoy) x14.7249.6 5.9%  
Price / Book Value ratio x7.314.0 52.0%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,38323,988 485.2%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m4,2141,605 262.6%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m31,4874,740 664.3%  
Other income Rs m5592 59.8%   
Total revenues Rs m31,5424,832 652.8%   
Gross profit Rs m10,060-130 -7,750.2%  
Depreciation Rs m722101 713.5%   
Interest Rs m370-   
Profit before tax Rs m9,356-139 -6,735.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m2,1605 42,440.1%   
Profit after tax Rs m7,194-5 -141,341.8%  
Gross profit margin %31.9-2.7 -1,166.6%  
Effective tax rate %23.1-3.7 -630.1%   
Net profit margin %22.8-0.1 -21,276.0%  
BALANCE SHEET DATA
Current assets Rs m15,0662,726 552.6%   
Current liabilities Rs m7,6742,435 315.2%   
Net working cap to sales %23.56.1 381.8%  
Current ratio x2.01.1 175.3%  
Inventory Days Days6774 90.8%  
Debtors Days Days4141 99.7%  
Net fixed assets Rs m8,2371,035 795.7%   
Share capital Rs m37750 754.0%   
"Free" reserves Rs m15,416942 1,635.9%   
Net worth Rs m16,0051,716 932.7%   
Long term debt Rs m00-   
Total assets Rs m24,5944,156 591.8%  
Interest coverage x255.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.31.1 112.3%   
Return on assets %29.4-0.1 -24,006.9%  
Return on equity %44.9-0.3 -15,153.8%  
Return on capital %58.70-  
Exports to sales %55.75.7 977.8%   
Imports to sales %10.46.5 161.3%   
Exports (fob) Rs m17,551270 6,495.5%   
Imports (cif) Rs m3,283306 1,071.8%   
Fx inflow Rs m17,811375 4,754.5%   
Fx outflow Rs m5,318470 1,131.1%   
Net fx Rs m12,493-96 -13,074.3%   
CASH FLOW
From Operations Rs m9,304-8 -114,863.0%  
From Investments Rs m-3,105-146 2,131.0%  
From Financial Activity Rs m-1,959862 -227.2%  
Net Cashflow Rs m4,240709 598.4%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 0.3 966.7%  
FIIs % 9.1 15.7 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 9.1 152.7%  
Shareholders   49,328 12,856 383.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  ABBOTT INDIA  STRIDES SHASUN LTD  WYETH LTD  TORRENT PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS